D Do oe es s l lo on ng g--t te er rm m o ox xy yg ge en n t th he er ra ap py y a af ff fe ec ct t q qu ua al li it ty y o of f l li if fe e i in n p pa at ti ie en nt ts s w wi it th h c ch hr ro on ni ic c o ob bs st tr ru uc ct ti iv ve e p pu ul lm mo on na ar ry y d di is se ea as se e a an nd d s se ev ve er re e h hy yp po ox x--a ae em mi ia a? ? ABSTRACT: Long-term oxygen therapy (LTOT) improves survival in patients with hypoxaemic chronic obstructive pulmonary disease (COPD), but previous studies using general health measures have shown no effect on quality of life (QoL). In this study, the effect of LTOT on QoL was assessed using a disease-specific health measure, the St George's Respiratory Questionnaire (SGRQ). Twenty three hypoxaemic COPD patients (15 females and 8 males) were studied before and after starting LTOT: median age 71 (range 47-82) yrs, mean ( The LTOT group had higher SGRQ total scores than controls (p<0.05) at all visits, implying lower QoL. Repeated measures analysis of variance showed no effect of LTOT on QoL over 6 months (F=0.43, p=0.79).In this study we detected no change in quality of life using a disease-specific health measure in patients with severe chronic obstructive pulmonary disease using an oxygen concentrator to provide long-term oxygen therapy. Eur Respir J., 1996Respir J., , 9, 2335Respir J., -2339 Long-term oxygen therapy (LTOT) is a well-established treatment for patients with chronic obstructive pulmonary disease (COPD) and severe hypoxaemia. Two large, randomized studies, the British Medical Research Council (MRC) study and the Nocturnal Oxygen Therapy Trial (NOTT) study from the USA, published in the early 1980s, established that LTOT for at least 15 h·day -1 can reduce mortality in these patients [1, 2]. Other studies have shown physiological benefits of LTOT, including reduction of pulmonary hypertension and secondary polycythaemia [3][4][5][6], and improvements in neuropsychological function [7,8].In addition to having a poor prognosis, patients with severe hypoxaemia and COPD suffer considerable functional disability. Several studies have shown that quality of life is impaired in patients with COPD and hypoxaemia [9][10][11]. Furthermore, in patients with moderateto-severe hypoxaemia, the quality of life score is related to the degree of hypoxaemia when measured using a disease-specific questionnaire [12]. However, the effect of LTOT on quality of life has not been clearly established. In an ancillary study to the NOTT study, there was no improvement in quality of life over 6 months in patients with hypoxic COPD treated with oxygen compared to age-matched controls without COPD [8]. This study used a general health questionnaire, the Sickness Impact Profile (SIP) [13]. In a recent study, this questionnaire did not discriminate between patients with different levels of hypoxia in contrast to a disease-specific measure whose scores were correlated with arterial oxygen tension Pa,O 2 [12]. It is possible that the use of an oxygen concentrator for the provisio...